Timothy J. Beavers

Timothy J. Beavers is an associate in Goodwin Procter's Intellectual Property Litigation practice, based in New York. His practice primarily focuses on patent, antitrust, and trade secret disputes in federal courts. He handles matters across a range of industries, including biotechnology, small and large molecule pharmaceuticals, biosimilars, medical devices, drug delivery, genomics technologies, and computer processing technologies.

Beavers works for both plaintiffs and defendants in patent disputes. His tracked cases include representing Tecan Genomics Inc. as a plaintiff in patent litigation, such as against QIAGEN Sciences LLC, which involves nucleic acid enrichment, genomics, and sequencing technologies. He has also represented clients as defendants in related administrative proceedings.

His experience extends to inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB), as evidenced by his involvement in cases such as Unified Patents v. Tecan Genomics Inc. and Unified Patents PTAB Data v. Tecan Genomics Inc. Beavers has also been noted for successfully arguing an appeal concerning a stay pending inter partes review on behalf of a healthcare manufacturer.

Notable experiences include successfully defending Teva Pharmaceuticals and Gilead Sciences in a federal jury verdict in antitrust litigation concerning generic HIV treatments. He was recognized for his oral argument in In re Lumify. Beavers earned his J.D., summa cum laude, from the Moritz College of Law at Ohio State University in 2020 and is admitted to the New York bar and the U.S. District Courts for the Southern and Eastern Districts of New York.